IRONWOOD PHARMACEUTICALS INC

Explore Ironwood Pharmaceuticals: Boston‑based biotech investing in cholesterol, GI, cardiovascular treatments, and pain meds, with a 52‑week high of $5.78 and a $712 M market cap.

Discover Ironwood Pharmaceuticals: a Boston‑based biotech firm innovating cholesterol, GI, heart, pain, and inflammation drugs—marketed on Nasdaq with a $709 M cap.

Explore Ironwood Pharmaceuticals’ biotech focus, stock volatility, valuation insights, and latest market moves—your concise guide to the company’s health‑sector dynamics.

Ironwood Pharmaceuticals Inc. remains a key player in the biotech sector, with a strategic focus on treating various diseases and a commitment to innovation, despite facing financial challenges and market volatility.

Ironwood Pharmaceuticals, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing pharmaceuticals for various medical conditions, with a market capitalization of approximately $123.63 million as of August 2025.

Ironwood Pharmaceuticals Inc faces significant financial challenges and uncertainty in the biotech sector, with a plummeting stock price and negative P/E ratio, but continues to push forward with ambitious drug development projects.

Ironwood Pharmaceuticals reported strong Q2 2025 performance, exceeding earnings and revenue estimates, and maintaining its full-year guidance for 2025.

Ironwood Pharmaceuticals is a biotech company focused on developing pharmaceuticals for various health conditions, with a stock price that has experienced significant fluctuations over the past year.